GlassScriptPhysician profile
Abraham D Derman
NPI 1891299038
$1,073.74
in general payments reported to CMS, 2019-2025
11 companies · $371 in 2025
The $371 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $238 · 2023: $174 · 2024: $290 · 2025: $371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $836.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $835.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $265.89 | 2024-2025 | Omnipod, Omnipod |
| Novo Nordisk INC | $254.78 | 2022-2024 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $173.89 | 2024-2025 | Farxiga |
| Abbvie INC. | $124.83 | 2023 | Vraylar |
| Lilly USA, LLC | $85.68 | 2024-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $60.75 | 2024 | |
| Neurocrine Biosciences, INC. | $27.89 | 2023 | Ingrezza |
| Baxter Healthcare | $25.33 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Glaxosmithkline, LLC. | $21.35 | 2023 | Shingrix, Arexvy |
| Meridian Bioscience INC. | $18.81 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $14.54 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abraham Derman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.